Janssen&Janssen schreef op 13 september 2022 20:14:
Iedereen heeft het wel over de spreektijd van pharming vandaag.
Maar het echte geld wordt donderdag voor pharming verdient, overigens deze link heb ik al eens gedeeld
Leniolisib: A Novel Drug Being Investigated for Treatment of APDS, a Rare Primary Immunodeficiency
A Pre-Approval Information Exchange (PIE) Webinar sponsored by Pharming.
Activated Phosphoinositide 3-kinase d Syndrome (APDS), is a rare PI that affects approximately 500 patients in the United States. This complex PI is caused by variants in the PI3Kd enzyme complex affecting both B cells and T cells.
This PIE webinar will
• Review the prevalence, etiology, clinical manifestations, and current management of APDS
• Introduce leniolisib, a novel drug being investigated for treatment of APDS
• Highlight results from the pivotal phase 3 clinical trial
This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this
webinar, you must be registered as a user of FormularyDecisions®.
Thursday, September 15, 2022, 2-3pm ET
www.amcp.org/calendar